Skip to content

Study · Non-randomized trial · n = 20 · 1999

7 results

[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix].

Felberbaum RE, Ludwig M, Diedrich K

Contraception, fertilite, sexualite (1992)1 Oct 1999Cited by 7 (Europe PMC)

PMID10605180 (opens in a new tab)PepBankPUB-10605180
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, cetrorelix satisfactorily suppressed gonadotrophins in 16 patients.

    In plain wordsIn women with uterine fibroids, cetrorelix lowered gonadotrophins satisfactorily in 16 patients.

    Peptide
    Cetrorelix
    Outcome
    DecreaseGonadotrophin suppression
    Study

    n = 20

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Patients with satisfactory suppression
    16 patients
    gonadotrophins suppression

    Source sentences

    Summary
    16 patients showed satisfactory suppression of gonadotrophins and sexual steroids.
    4 context sentences
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, cetrorelix satisfactorily suppressed sex steroids in 16 patients.

    In plain wordsIn women with uterine fibroids, cetrorelix lowered sex steroids satisfactorily in 16 patients.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSex steroid suppression
    Study

    n = 20

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Patients with satisfactory suppression
    16 patients
    sex steroids suppression

    Source sentences

    Summary
    16 patients showed satisfactory suppression of gonadotrophins and sexual steroids.
    4 context sentences
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  3. 03HumanNon-randomized trialSafety outcome

    In women with uterine fibroids, no flare-up effect was observed during cetrorelix treatment.

    In plain wordsIn women with uterine fibroids, no flare-up effect was observed during cetrorelix treatment.

    Peptide
    Cetrorelix
    Outcome
    Not applicableFlare-up
    Study

    n = 20

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Source sentences

    Summary
    No flare up effect was to be observed.
    4 context sentences
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids and satisfactory hormone suppression, maximum fibroid size reduction with cetrorelix was 33.5% at treatment end.

    In plain wordsIn women with uterine fibroids and satisfactory hormone suppression, cetrorelix reduced fibroid size by a maximum of 33.5%.

    Peptide
    Cetrorelix
    Outcome
    DecreaseMaximum fibroid size reduction at treatment end
    Study

    n = 16

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Maximum size reduction
    33.5%
    end of treatment

    Source sentences

    Summary
    In this group of patients the maximum reduction in fibroids size was of 33.5% at the end of treatment.
    5 context sentences
    Summary · context
    16 patients showed satisfactory suppression of gonadotrophins and sexual steroids.
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids and satisfactory hormone suppression, fibroid size fell 31.3% after 14 days of cetrorelix treatment.

    In plain wordsIn women with uterine fibroids and satisfactory hormone suppression, fibroid size fell 31.3% after 14 days of cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreaseFibroid size reduction after 14 days
    Study

    n = 16

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Size reduction
    31.3%
    14 days

    Source sentences

    Summary
    After 14 days of treatment the reduction was of 31.3%.
    5 context sentences
    Summary · context
    In this group of patients the maximum reduction in fibroids size was of 33.5% at the end of treatment.
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  6. 06HumanNon-randomized trialEfficacy outcome

    In good responders with uterine fibroids, largest fibroid volume after 14 days of cetrorelix was 56.7% of its initial value.

    In plain wordsIn good responders with uterine fibroids, the largest fibroid reached 56.7% of its initial volume after 14 days of cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLargest fibroid volume in good responders
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Residual volume
    56.7%
    initial assessment

    Source sentences

    Summary
    Within the group of good responders (reduction of fibroids size > 20%) the volume of the biggest fibroid after 14 days of treatment was of 56.7% of the initial assessment.
    4 context sentences
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with uterine fibroids, MRI showed mean shrinkage with cetrorelix of 25.4% of initial volume.

    In plain wordsIn women with uterine fibroids, MRI showed average shrinkage with cetrorelix of 25.4% of initial volume.

    Peptide
    Cetrorelix
    Outcome
    DecreaseMRI fibroid shrinkage
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    60 mg initially, then 60 mg or 30 mg · intramuscular · six or eight weeksAs given in this study (human).

    Measurements

    Mean shrinkage
    25.4%
    MRI

    Source sentences

    Summary
    Although MRI showed minor mean shrinkage rates of only 25.4% of the initial volume, these differences in comparison to transvaginal sonography were not statistically significant.
    4 context sentences
    Summary · context
    A depot preparation of the LHRH-antagonist Cetrorelix was used for the preoperative treatment of 20 premenopausal women with symptomatic uterine fibroids to undergo surgery.
    Summary · context
    In an open, prospective and randomised study, 60 mg of this depot preparation were administered i.m. at the second day of cycle.
    Summary · context
    Patients were randomised for a second dosage of 60 mg or 30 mg to be injected on day 21 or day 28 of treatment according to the degree of estradiols' suppression (< 50 pg/mL).
    Summary · context
    The operation was carried out after six or eight weeks of treatment according to the timing of second dosages administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.